Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics' Q1 Loss Nearly Doubles

NEW YORK (GenomeWeb News) – Rosetta Genomics today reported that its first-quarter net loss nearly doubled year over year as the firm gears up for initial diagnostic product launches.
 
The Rehovot, Israel-based firm had no revenues for the three-month period ended March 31. The firm expects to have its initial microRNA-based diagnostic tests for cancer approved for use in CLIA labs by the end of this year.
 
Specifically, it plans to seek regulatory approval later this year for CLIA tests for cancer of unknown primary and for differentiating between mesothelioma and adenocarcinoma.
 
Rosetta’s net loss increased to $3.9 million, or $.33 per share, from $2 million, or $.23 per share, in the first quarter of 2007.
 
The firm’s R&D expenses doubled to $2.4 million from $1.2 million, and its costs for marketing, business development, and general and administrative functions rose 26.4 percent to $1.34 million from $1.06 million.
 
Rosetta finished the quarter with $9.5 million in cash and cash equivalents.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.